



## MANAGEMENT TEAM

Christopher J. Moreau  
Chief Executive Officer

Dr. Christopher Bryan, PhD  
Vice President Research & Operations

Michael Sadhra, CA  
Chief Financial Officer & Director

Dr. Ahmed Khalil, PhD  
Chief Medical Officer

## BUSINESS ADVISORY BOARD

U.S. Ambassador (Rtd)  
Howard Gutman

## MEDICAL & SCIENTIFIC ADVISORY BOARD

Dr. Mark Swaim, MD, PhD

Jacky Smith, MB, ChB, FRCP, PhD

Dr. Martin Kolb, MD

## BOARD OF DIRECTORS

Christopher J. Moreau, CEO

Raj Attariwala, MD, PhD

Michael Sadhra, CA

David Levine

## STOCK INFORMATION

(March 11, 2021)

Shares O/S:	167 Million
Market Cap:	C\$ 32 Million
Recent Price:	C\$ 0.19

## TRADING SYMBOLS

CSE: AGN

OTCQB: AGNPF

XFRA: AGW

## INVESTOR INQUIRIES

Christopher J. Moreau, CEO

604.398.4175

chris@algernonpharmaceuticals.com

## HEAD OFFICE

Algernon Pharmaceuticals Inc.  
Suite 915-700 West Pender St.  
Vancouver, BC, Canada, V6C 1G8

## CORPORATE PRESENTATION

## COMPANY OVERVIEW

Algernon is a drug repurposing company, investigating drugs that have an established safety history for new disease applications, moving them efficiently and safely into new human trials, and seeking new regulatory approvals in billion dollar global disease markets. Repurposing offers several benefits over traditional drug development including a reduction in investment and risk (repurposed compounds have a much lower risk of failing in human trials as a result of safety issues), shorter research periods and a longer active patent life.

Our program specifically investigates compounds that have never been approved in the U.S. or Europe. We protect our lead compounds with method of use, dosing and new formulation patents, as well as composition of matter patents that include derivatives and analogues. The Algernon model is highly capital efficient and the company has assembled an experienced management team, a globally recognized medical and scientific advisory board, and a business advisory board.

## ALGERNON'S CLINICAL RESEARCH PROGRAMS

### STROKE

Algernon has established a clinical research program for the treatment of stroke focused on AP-188 ("N,N-Dimethyltryptamine or DMT"), a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin). Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021.



### IDIOPATHIC PULMONARY FIBROSIS (IPF) AND CHRONIC COUGH

Algernon is investigating NP-120 (Ifenprodil) in a proof-of-concept Phase 2 human trial to determine the efficacy of Ifenprodil in the preservation of lung function in IPF patients (including biomarkers of fibrosis) and its associated cough. There are 5 sites in total participating in the study with 3 located in Australia and 2 in New Zealand.

Ifenprodil has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a murine model of IPF. In addition, Ifenprodil significantly reduced both cough frequency and onset in a guinea pig acute cough model.

### COVID-19

The company has been conducting a 150 patient Phase 2b/3 multi-national study of Ifenprodil for COVID-19.

The Company announced topline data for the Phase 2b part of its Phase 2b/3 Ifenprodil COVID-19 Study, on March 31, 2021. The Company has also filed an end of Phase 2 meeting request (EOP2) with the U.S. Food and Drug Administration to determine its next steps.

